TrialSignal
Clinical trial intelligence report
Improving Pre-operative Systemic Therapy for Human Epidermal Growth Factor Receptor 2 (HER2) Amplified Breast Cancer Part of a Platform of Translational Phase II Trials Based on Molecular Subtypes
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT03894007
Status
TERMINATED
Phase
PHASE2
Sponsor
Renske Altena
Executive brief
Investment-Ready Snapshot
This is a phase 2 study evaluating medical treatment before surgery in HER2-amplified early breast cancer patients. Patients receive chemotherapy with HER2-targeted antibodies and are randomised to receive the checkpoint inhibitor atezolizumab or not.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT03894007
Indication
Early-stage Breast Cancer
Modality
small molecule
Target
Docetaxel, Carboplatin, Trastuzumab, Pertuzumab, Epirubicin, Cyclophosphamide, Atezolizumab, Trastuzumab emtansine, Paclitaxel
Intervention
Docetaxel, Carboplatin, Trastuzumab, Pertuzumab, Epirubicin, Cyclophosphamide, Atezolizumab, Trastuzumab emtansine, Paclitaxel
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.